Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CD24P4
REST API REST API
Homo sapiens
CD24P4 is differentially expressed in 291 experiments: 163 organism parts: bone marrow, kidney, ... (161 more);, 217 disease states: normal, breast carcinoma, ... (215 more);, 109 cell types 609 cell lines 43 compound treatments and 75 other conditions.
Synonyms CD24L4
Search EB-eye ENSG00000185275
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, ... (45 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
MCF-7
1
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
SW480
1
3
E-GEOD-18005, E-MEXP-1014, E-GEOD-2509, E-MTAB-37
H441
2
E-GEOD-16194, E-MTAB-62
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
603 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-120, E-GEOD-20677, ... (52 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-18147, E-GEOD-20033, E-GEOD-18265
monocyte
3
E-GEOD-11755, E-GEOD-22373, E-GEOD-7307
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
CD8+ T cell
1
2
E-AFMX-5, E-GEOD-19069, E-GEOD-6740
103 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-TABM-15, E-GEOD-16363, E-MTAB-680, ... (50 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-231
T-cell acute lymphoblastic leukemia
2
E-MTAB-37, E-GEOD-1577
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-37, E-MTAB-62
malignant melanoma
2
E-GEOD-3189, E-MTAB-62
211 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-GEOD-3720, E-GEOD-5824, E-MEXP-2417, ... (22 experiments)

Factor Value U/D Experiments
17beta-estradiol
3
2
E-GEOD-4006, E-GEOD-4668
RA
1
E-MEXP-2417
4-hydroxytamoxifen
2
1
E-MEXP-2241
FLAP
1
E-GEOD-3202
ethanol
1
E-MEXP-2241
ZMYM2/FGFR1
1
E-GEOD-15811
37 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-2509, E-MEXP-2280

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-MTAB-108, ... (6 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-22056, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-GEOD-20540, E-GEOD-22278, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716, E-GEOD-2748 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-TABM-740, E-MEXP-2069, ... (35 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-9723, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-3407, E-GEOD-17636

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-19743, E-TABM-311, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-TABM-43, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.382 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM